Headache attributed to a substance or its withdrawal

Handbook of Clinical Neurology

Volumn 97, Issue C, 2010, Pages 589-599

  Diener, Hans Christoph ^a   Katsarava, Zaza ^a   Limmroth, Volker ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b Medical Clinic Köln Merheim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT;

HEADACHE; HUMAN; MIGRAINE; PREVALENCE; SECONDARY HEADACHE;

ANALGESICS; HEADACHE; HEADACHE DISORDERS, SECONDARY; HUMANS; MIGRAINE DISORDERS; PREVALENCE;

EID: 77956292352     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(10)97051-6     Document Type: Book

References (113)

1. Ala-Hurula V., Milia V., Hokkanen E. Ergotamine abuse: results of ergotamine discontinuation, with special reference to the plasma concentrations. Cephalalgia 1982, 2:189-195.
2. Andersson P.G. Ergotism - the clinical picture. Drug-Induced Headache 1988, 16-19. Springer, Heidelberg. H.C. Diener, M. Wilkinson (Eds.).
3. Atasoy H.T., Atasoy N., Unal A.E., et al. Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain 2005, 9:285-291.
4. Ayzenberg I., Obermann M., Nyhuis P., et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006, 26:1106-1114.
5. Ayzenberg I., Obermann M., Leineweber K., et al. Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans. J Headache Pain 2008, 9:109-112.
6. Bahra A., Walsh M., Menon S., et al. Does chronic daily headache arise de novo in association with regular analgesic use?. Headache 2003, 43:179-190.
7. Baumgartner C., Wessely P., Bingol C., et al. Long-term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 1989, 29:510-514.
8. Bendtsen L., Jensen R., Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headache. Arch Neurol 1996, 53:373-376.
9. Bigal M.E., Rapoport A.M., Sheftell F.D., et al. Transformed migraine and medication overuse in a tertiary headache center - clinical characteristics and treatment outcomes. Cephalalgia 2004, 24:483-490.
10. Bigal M.E., Serrano D., Buse D., et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008, 48:1157-1168.
11. Bøe M.G., Mygland A., Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology 2007, 69:26-31.
12. Castillo J., Munoz P., Guitera V., et al. Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190-196.
13. Catarci T., Fiacco F., Argentino C., et al. Ergotamine-induced headache can be sustained by sumatriptan daily intake. Cephalalgia 1994, 14:374-375.
14. Colas R., Munoz P., Temprano R., et al. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004, 27:1338-1342.
15. Coskun O., Ucler S., Cavdar L., et al. Effect of valproic acid on withdrawal therapy in patients with overuse of chronic daily headache medications. J Clin Neurosci 2007, 14:334-339.
16. 2 laser stimulation in chronic tension-type headache. Pain 2003, 104:1111-1119.
17. Diaz-Mitoma F., Vanast W.J., Tyrrell D.L. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet 1987, 1:411-415.
18. Dichgans J., Diener H.C., Gerber W.D., et al. Chronic analgesic-induced headache. Dtsch Med Wochenschr 1984, 109:369-373.
19. Diener H.C., Dahlof CG. Headache associated with chronic use of substances. The Headaches 1999, 871-878. Lippincott, Williams & Wilkins, Philadelphia. 2nd edn. J. Olesen, P. Tfelt-Hansen, K.M. Welch (Eds.).
20. Diener H.C., Wilkinson M. Drug-Induced Headache 1988, 115-123. Springer, New York.
21. Diener H.C., Buhler K., Dichgans J., et al. Analgetikainduzierter Dauerkopfschmerz. Existiert eine kritische Dosis?. Arzneimitteltherapie 1988, 6:156-164.
22. Diener H.C., Dichgans J., Scholz E., et al. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989, 236:9-14.
23. Diener H.C., Haab J., Peters C., et al. Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache 1990, 31:205-209.
24. Diener H.C., Bussone G., Van Oene J.C., et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007, 27:814-823.
25. Dobson C.F., Tohyama Y., Diksic M., et al. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 2004, 24:2-11.
26. Drucker P., Tepper S. Daily sumatriptan for detoxification from rebound. Headache 1998, 38:687-690.
27. Evers S., Bauer B., Suhr B., et al. The epidemiology of sumatriptan abuse. Headache Treatment: Trial Methodology and New Drugs. Frontiers in Headache Research 1997, Vol. 6:149-152. Lippincott Williams & Wilkins, Philadelphia. J. Olesen, P. Tfelt-Hansen (Eds.).
28. Evers S., Suhr B., Bauer B., et al. A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J Neurol 1999, 246:802-809.
29. Fanciullacci M., Alessandri M., Pietrini U., et al. Long-term ergotamine abuse: effect on adrenergically induced mydriasis. Clin Pharm Ther 1992, 51:302-327.
30. Fisher M.A., Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology 1997, 48:1156-1160.
31. Fritsche G., Eberl A., Katsarava Z., et al. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001, 45:229-235.
32. Fumal A., Laureys S., Di Clemente L., et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006, 129:543-550.
33. Gaist D., Hallas J., Sindrup S.H., et al. Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996, 3:161-165.
34. Gaist D., Tsiropoulus I., Sindrup S.H., et al. Inappropriate use of sumatriptan: population based register and interview study. BMJ 1998, 316:1352-1353.
35. Goadsby P.J. How do the currently used prophylactic agents work in migraine?. Cephalalgia 1997, 17:85-92.
36. Granella F., Farina S., Malferrari G., et al. Drug abuse in chronic headache: a clinico-epidemiologic study. Cephalalgia 1987, 7:15-19.
37. Grazzi L., Andrasik F., D'Amico D., et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 2002, 42:483-490.
38. Griffiths R.R., Woodson P.P. Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacology 1988, 94:437-451.
39. Griffiths R.R., Woodson P.P. Reinforcing properties of caffeine: studies in humans and laboratory animals. Pharmacol Biochem Behav 1998, 29:419-427.
40. Gutzwiller F., Zemp E. Der Analgetikakonsum in der Bevölkerung und socioökonomische Aspekte des Analgetikaabusus. Das Analgetikasyndrom 1986, 197. Thieme, Stuttgart. M.J. Mihatsch (Ed.).
41. Haag G., Baar H., Grotemeyer K.H., et al. Prophylaxe und Therapie des medikamenteninduzierten Dauerkopfschmerzes. Schmerz 1999, 13:52-57.
42. Hagen K., Vatten L., Stovner L.J., et al. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway. Cephalalgia 2002, 22:672-679.
43. Hagen K., Albretsen C., Vilming S., et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia 2009, 29:221-232.
44. Headache Classification Committee of the International Headache Society Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988, 8:1-93.
45. Headache Classification Subcommittee of the International Headache Society The international classification of headache disorders, 2nd edn. Cephalalgia 2004, 24:1-160.
46. Hering R., Steiner T.J. Abrupt outpatient withdrawal of medication in analgesic-abusing migraineurs. Lancet 1991, 337:1442-1443.
47. Katsarava Z., Fritsche G., Muessig M., et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001, 57:1694-1698.
48. Katsarava Z., Limmroth V., Finke M., et al. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology 2003, 60:1682-1683.
49. Katsarava Z., Schneeweiss S., Kurth T., et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004, 62:788-790.
50. Kaube H., May A., Diener H.C., et al. Sumatriptan misuse in daily chronic headache. BMJ 1994, 308:1573.
51. Kavuk I., Weimar C., Kim B.T., et al. One-year prevalence and socio-cultural aspects of chronic headache in Turkish immigrants and German natives. Cephalalgia 2006, 26:1177-1181.
52. Krymchantowski A.V., Barbosa J.S. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000, 20:107-113.
53. Lance F., Parkes C., Wilkinson M. Does analgesic abuse cause headache de novo?. Headache 1988, 38:61-62.
54. Lanteri-Minet M., Auray J.P., El Hasnaoui A., et al. Prevalence and description of chronic daily headache in the general population in France. Pain 2003, 102:143-149.
55. Limmroth V., Kazarawa S., Fritsche G., et al. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet 1999, 353:378.
56. Limmroth V., Katsarava Z., Fritsche G., et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002, 59:1011-1014.
57. Linton-Dahlof P., Linde M., Dahlof C. Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication: a retrospective study. Cephalalgia 2000, 20:658-662.
58. Lu S.R., Fuh J.L., Chen W.T., et al. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia 2001, 21:980-986.
59. Lucas C., Auray J.P., Gaudin A.F., et al. Use and misuse of triptans in France: data from the GRIM2000 population survey. Cephalalgia 2004, 24:197-205.
60. Mathew N.T. Amelioration of ergotamine withdrawal with naproxen. Headache 1987, 27:130-133.
61. Mathew N.T., Ali S. Valproate in the treatment of persistent chronic daily headache. An open labeled study. Headache 1991, 31:71-74.
62. Mathew N.T., Kurman R., Perez F. Drug induced refractory headache - clinical features and management. Headache 1990, 30:634-638.
63. Meskunas C.A., Tepper S.J., Rapoport A.M., et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006, 46:766-772.
64. Micieli G., Manzoni G.C., Granella F., et al. Clinical and epidemiological observations on drug abuse in headache patients. Drug-Induced Headache 1988, 20-28. Springer, New York. H.C. Diener, M. Wilkinson (Eds.).
65. Moore A.J., Shevell M. Chronic daily headaches in pediatric neurology practice. J Child Neurol 2004, 19:925-929.
66. Newman L.C., Lipton R.B., Russell M., et al. Hemicrania continua: attacks may alternate sides. Headache 1992, 32:237-238.
67. Newman L.C., Lipton R.B., Solomon S. Hemicrania continua: 7 new cases and a literature review. Headache 1993, 32:267.
68. Olesen J., Lipton R.B. Headache classification update. Curr Opin Neurol 2004, 17:275-282.
69. Olesen J., Bousser M.G., Diener H.C., et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006, 26:742-746.
70. Paemeleire K., Bahra A., Evers S., et al. Medication-overuse headache in patients with cluster headache. Neurology 2006, 67:109-113.
71. Park J.W., Kim J.S., Kim Y.I., et al. Serotonergic activity contributes to analgesic overuse in chronic tension-type headache. Headache 2005, 45:1229-1235.
72. Peters G.A., Horton B.T. Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc Staff Meet Mayo Clin 1951, 26:153-161.
73. Pini L.A., Trenti T. Case report: does chronic use of sumatriptan induce dependence?. Headache 1994, 34:600-601.
74. Pini L.A., Cicero A.F., Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 2001, 21:878-883.
75. Prencipe M., Casini A.R., Ferretti C., et al. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry 2001, 70:377-381.
76. Queiroz L.P., Peres M.F., Kowacs F., et al. Chronic daily headache in Brazil: a nationwide population-based study. Cephalalgia 2008, 28:1264-1269.
77. Radat F., Creac'h C., Swendsen J.D., et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2005, 25:519-522.
78. Rapoport A., Weeks R., Sheftell F. Analgesic rebound headache: theoretical and practical implications. Proceedings Second International Headache Congress 1985, 448-449. Scandinavian University Press, Oslo. J. Olesen, P. Tfelt-Hansen, K. Jensen (Eds.).
79. Rapoport A., Stang P., Gutterman D.L., et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996, 36:14-19.
80. Raskin N.H. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986, 36:995-997.
81. Reuter U., Salomone S., Ickstein G.W., et al. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia 2004, 24:398-407.
82. Robinson R.G. Pain relief for headaches. Is self-medication a problem?. Can Fam Physician 1993, 39:867-868.
83. Rossi P., Di Lorenzo C., Faroni J., et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia 2006, 26:1097-1105.
84. Rossi P., Faroni J.V., Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 2008, 28:1196-1200.
85. Rossi C., Pini L.A., Cupini M.L., et al. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol 2008, 64:1-8.
86. Saper J.R., Jones J.M. Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol 1986, 9:244-256.
87. Scher A.I., Stewart W.F., Ricci J.A., et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106:81-89.
88. Scher A.I., Stewart W.F., Lipton R.B. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 2004, 63:2022-2027.
89. Schmidt-Wilcke T., Leinisch E., Straube A., et al. Gray matter decrease in patients with chronic tension type headache. Neurology 2005, 65:1483-1486.
90. Schnider P., Aull S., Baumgartner C., et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five year follow-up. Cephalalgia 1996, 16:481-485.
91. Schwartz B.S., Stewart W.F., Simon D., et al. Epidemiology of tension-type headache. JAMA 1998, 279:381-383.
92. Schwarz A., Farber U., Glaeske G. Daten zu Analgetikakonsum und Analgetikanephropathie in der Bundesrepublik. Öffentliches Gesundheitswesen 1985, 47:298.
93. Silberstein S.D., Silberstein J.R. Chronic daily headache: long-term prognosis following inpatient treatment with repetitive intravenous DHE. Headache 1992, 32:439-445.
94. Silberstein S.D., Schulman E.A., McFaden Hopkins M. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990, 30:334-339.
95. Silberstein S.D., Olesen J., Bousser M.G., et al. The International Classification of Headache Disorders, 2nd Edition (ICHD-II) - revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005, 25:460-465.
96. Silverman K., Evans S.M., Strain E.C., et al. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992, 327:1109-1114.
97. Silvestrini M., Bartolini M., Coccia M., et al. Topiramate in the treatment of chronic migraine. Cephalalgia 2003, 23:820-824.
98. Srikiatkhachorn A., Anthony M. Platelet serotonin in patients with analgesic-induced headache. Cephalalgia 1996, 16:423-426.
99. Srikiatkhachorn A., Tarasub N., Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache 2000, 40:343-350.
100. Suhr B., Evers S., Bauer B., et al. Drug-induced headache: long-term results of stationary versus ambulatory withdrawal therapy. Cephalalgia 1999, 19:44-49.
101. Tfelt-Hansen P. Prophylactic treatment of migraine: evaluation of clinical trials and choice among drugs. Cephalalgia 1995, 15:29-32.
102. Tfelt-Hansen P., Krabbe A.A. Ergotamine abuse: do patients benefit from withdrawal?. Cephalalgia 1981, 1:29-31.
103. Tohyama Y., Yamane F., Fikre Merid M., et al. Effects of serotonin receptor agonists, TFMPP and CGS12066B, on regional serotonin synthesis in the rat brain: an autoradiographic study. J Neurochem 2002, 80:788-798.
104. Tribl G.G., Schnider P., Wober C., et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache?. Cephalalgia 2001, 21:691-696.
105. van Dusseldorp M., Katan M.B. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial. BMJ 1990, 300:1558-1559.
106. Wang S.J., Fuh J.L., Lu S.R., et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 2000, 54:314-319.
107. Wang S.J., Fuh J.L., Lu S.R., et al. Chronic daily headache in adolescents. Prevalence, impact, and medication overuse. Neurology 2006, 66:193-197.
108. Wiendels N.J., Knuistingh Neven A., Rosendaal F.R., et al. Chronic frequent headache in the general population: prevalence and associated factors. Cephalalgia 2006, 26:1434-1442.
109. Williams D.R., Stark R.J. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003, 23:963-971.
110. Zeeberg P., Olesen J., Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 2006, 66:1894-1898.
111. Zidverc-Trajkovic J., Pekmezovic T., Jovanovic Z., et al. Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia 2007, 27:1219-1225.
112. Ziegler D.K. Opiate and opioid use in patients with refractory headache. Cephalalgia 1994, 14:5-10.
113. Zwart J.A., Dyb G., Hagen K., et al. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003, 61:160-164.